Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification

Integral pharmacological management of CKD-MBD II

Autor/a

Bover, Jordi

Ureña-Torres, Pablo

Lloret, María Jesús

Ruiz, C.

DaSilva, I.

Diaz-Encarnacion, MM.

Mercado, C.

Mateu, S.

Fernández i Giráldez, Elvira

Ballarín, José

Data de publicació

2018-04-30T08:07:47Z

2018-04-30T08:07:47Z

2016-07-31

2018-04-30T08:07:49Z



Resum

INTRODUCTION: Chronic kidney disease-mineral and bone disorders (CKD-MBD) are associated with costly complications and dismal hard-outcomes. AREAS COVERED: In two comprehensive articles we review contemporary and future pharmacological options for treatment of phosphate (P) imbalance (part 1) and hyperparathyroidism (this part 2), taking into account CKD-accelerated cardiovascular calcification (CVC) processes. EXPERT OPINION: Improvements in CKD-MBD require an integral approach, addressing all three components of the CKD-MBD triad. Here, initial guidance to control hyperparathyroidism is provided, taking into account the presence/absence of CVC. We include also measures for patients at risk of adynamic bone disease or suffering from calciphylaxis. Many epidemiological studies (relating to vitamin D) and thorough analyses of recent randomized clinical trials (of cinacalcet) point towards benefits of attempting to improve biochemical parameters while trying to, at least, avoid progression of CVC by more rational use of intestinal P-binders and low-dose vitamin D derivatives and/or calcimimetics. This approach does not seem to be far away from significantly improving hard-outcomes, at least in the dialysis population. The availability of new drugs and the performance of randomized clinical trials should ultimately lead to define earlier, clearer, and more cost-effective patient stratification and biochemical targets with consequent significant clinical improvements.


J Bover belongs to the Spanish National Network of Kidney Research RedinRen (RD06/0016/0001 and RD12/0021/0033) and the Spanish National Biobank network RD09/0076/00064. He also belongs to the Catalan Nephrology Research Group AGAUR 2009 SGR-1116. J Bover and M.M. Diaz-Encarnacion collaborate with the Spanish ‘Fundación Iñigo Alvarez de Toledo’ (FRIAT)

Tipus de document

Article
Versió acceptada

Llengua

Anglès

Matèries i paraules clau

Chronic kidney disease; CKD-MBD; Phosphate

Publicat per

Taylor & Francis

Documents relacionats

Versió postprint del document publicat a: https://doi.org/10.1080/14656566.2016.1182985

Expert Opinion On Pharmacotherapy, 2016, vol. 17, num. 10, p. 1363-1373

Drets

(c) Taylor & Francis, 2016

Aquest element apareix en la col·lecció o col·leccions següent(s)